FDA Expected to Issue Draft Guidance on Decentralized Trials in 2021
May 4, 2021
Details of the FDA’s draft guidance on the operation of decentralized clinical trials due out this year are starting to emerge, with an expected emphasis on endpoint analysis, data quality and control, and the appropriate use of electronic informed consent (eConsent).